- PRIMEtime: an epidemiological model for informing diet and obesity policy 1
- 2
- 3 Linda J Cobiac
- 4 Senior Research Fellow
- 5 School of Medicine and Dentistry
- 6 **Griffith University**
- 7
- 8 Cherry Law
- 9 Lecturer
- 10 Department of Agri-Food Economics and Marketing
- 11 University of Reading
- 12
- 13 Peter Scarborough
- 14 **Professor of Population Health**
- 15 Nuffield Department of Population Health
- 16 University of Oxford
- 17
- 18 Funding:
- 19 This project was supported by the NIHR Biomedical Research Centre at Oxford (IS-BRC-1215-20008)
- 20 and an NIHR project grant for an evaluation of the UK Soft Drinks Industry Levy (16/130/01).
- 21 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

22 Abstract

Background: Mathematical modelling can play a vital role in guiding public health action. In this paper, we provide an overview of the revised and updated PRIMEtime model, a tool for evaluating health and economic impacts of policies impacting on diet and obesity. We provide guidance on populating PRIMEtime with country-specific data; and illustrate its validation and implementation in evaluating a combination of interventions in the UK: a sugar-sweetened beverage (SSB) tax; a ban on television advertising of unhealthy foods; and a weight loss program.

29 Methods: PRIMEtime uses routinely available epidemiological data to simulate the effects of changes 30 in diet and obesity on 19 non-communicable diseases, in open- or closed-population cohorts, over 31 time horizons from 1 year to a lifetime. From these simulations, the model can estimate impact of a 32 policy on population health (obesity prevalence, cases of disease averted, quality-adjusted life years), 33 health and social care costs, and economic measures (net monetary benefit, cost-effectiveness ratios). We populated PRIMEtime with UK data and validated epidemiological predictions against two 34 35 published data collections. We then evaluated three current obesity intervention policies based on 36 estimates of effectiveness from published evaluation studies.

37 **Results**: There was considerable variation in the modelled impact of interventions on prevalence of 38 obesity and subsequent changes in health and the need for health care: restrictions on TV advertising 39 of unhealthy foods to children led to the largest reductions in obesity prevalence; but the SSB tax, 40 which also targeted adults, had the biggest benefits in reducing obesity-related disease; and the 41 weight loss program, while having very small impact on obesity prevalence at the population scale, 42 had large and immediate benefits in improving health and reducing health sector spending. From a 43 health sector perspective, the combination of interventions produced a favourable net monetary benefit of £31,400 (12,200 to 50,700) million. But the combined effect in reducing prevalence of 44 45 overweight and obesity, was not estimated to reach more than 0.81 percentage points (95%

46 uncertainty interval: 0.21 to 1.4) for males and 0.95 percentage points (0.24 to 1.7) for females by
47 2050.

48 **Conclusions**:

Diet and obesity interventions have the potential to improve population health and reduce health sector spending both immediately and in the long-term. Models such as PRIMEtime can be used to evaluate the economic merits of intervention strategies and determine how best to combine interventions to achieve maximum population benefit. But with almost a third of children and twothirds of adults currently overweight or obese, we need to broaden the application of public health models to evaluating the structural and systemic changes that are needed in our society to address the underlying drivers of the obesity epidemic.

57 Introduction

58 Overweight and obesity have been recognised as a cause of poor health for over 2000 years.[1] But in 59 the early times, it is likely the overall prevalence of obesity in the population was low; with 60 malnutrition and underweight a greater cause of ill-health and premature loss of life. It is only in the last two decades that the number of overweight and obese adults worldwide have outnumbered 61 62 those who are underweight.[2] Globally, 39% of adults and 18% of children and adolescents are now 63 estimated to be overweight or obese.[3] This is associated with an excess 4.7 million deaths and 147.7 64 million disability-adjusted life years, with around 90% of this burden due to cardiovascular diseases, 65 diabetes, related kidney diseases, and cancers.[4]

66 Like many high-income countries, the United Kingdom has been at the leading edge of the transition 67 to obesity. By the time the World Health Organization recognised the growing prevalence of overweight and obesity as a 'global epidemic' in 1998, around 3 in 5 adults in England were already 68 either overweight or obese. [5] While successive governments have attempted to address the problem 69 70 over the last 30 years, including 14 strategy documents and 689 proposed policies and programs, 71 efforts have so far failed to turn the tide.[6, 7] Although rapid upwards trends in obesity prevalence 72 of the 1990s had flattened by the early 2000s, projection models suggest that prevalence of 73 overweight and obesity will remain high until at least 2035, without more effective action.[8]

Mathematical modelling can play a vital role in guiding public health action,[9] as we have witnessed in the COVD-19 pandemic. While an epidemic of obesity may be slower-moving than an epidemic of an infectious disease, the informative value of modelling is no less important. Models can help us understand what the likely consequences of an intervention are, how confident we can be in the predicted outcomes, and what are the risks associated with the decision to act (or not act).[10] In the absence of modelling, decision-making is little more than blind guesswork; but modelling will only be of value if the model's design, its inputs and outputs are clearly communicated, and there is

transparency in the assumptions that have been made, whether explicit in model parameters or
implicit in the structural design.[9, 10]

PRIMEtime is an epidemiological modelling tool that was developed in the UK for simulating diet and 83 84 obesity interventions and scenarios. The model was initially developed in 2014 for examining impacts 85 of changes in diet and obesity on population health, including non-communicable disease rates and 86 life expectancy, [11] and this was later expanded to include impacts on quality of life and costs of 87 health and social care.[12] The model has been used to examine potential impacts of a range of 88 interventions and scenarios, including a targeted weight loss program, regulation of television 89 advertising of unhealthy foods to children, salt reduction, evaluating changes to dietary guidelines and 90 identifying most environmentally sustainable dietary patterns.[11-16]

91 In recent years, we have made a number of updates to the PRIMEtime model. These include new 92 features to capture background trends in obesity and disease rates, as well as updates of model 93 parameters to incorporate the latest evidence on risks of disease associated with diet and obesity, 94 and to capture the latest data on risk factor and disease rates in the UK. In addition, we have modified 95 the cohort simulation to include options for both open- and closed-cohort simulation. While 96 previously a closed-cohort simulation model, allowing users to examine changing health and cost 97 consequences for an adult population cohort ageing through time, PRIMEtime now additionally incorporates open-cohort simulation of outcomes for children and future birth cohorts out to 2050. 98 99 This feature enables users to examine impacts of interventions on population prevalence of 100 overweight and obesity and population rates of disease into the future, and potentially facilitates 101 linkage of PRIMEtime with economic and environmental simulation models.

102 In this paper we describe the updated PRIMEtime model and illustrate its use in evaluating a 103 combination of interventions: a sugar-sweetened beverage tax; a ban on television advertising of 104 unhealthy foods; and a weight loss program. These are all interventions that have been implemented 105 or recommended in the government's latest obesity strategy.[17] This work is not intended to be a

comprehensive evaluation of all potential obesity intervention strategies, rather the aim is to provide
 transparency on the model's design and input parameters, to illustrate how the model can be used,
 and discuss how this and other modelling may be developed and better integrated into policy in the
 future.

110 Methods

111 The PRIMEtime model

112 Model Design

The PRIMEtime modelling approach (Figure 1) consists of three interlinked components: (1) a risk factor exposure module, which quantifies the effect of change in prevalence of one or more risk factors on incidence of related diseases; (2) a series of disease models, which simulate changing incidence, prevalence and mortality of diseases related to the modelled risk factors; (3) a lifetable, which simulates overall impacts on the population, health and social care system, due to the changing disease epidemiology.

119 Risk factor exposure

When an intervention is simulated in PRIMEtime, the magnitude of impact on disease associated with a risk factor (e.g. high body mass index) depends on a combination of variables: (1) the baseline population exposure to the risk factor; (2) the measured effect of the intervention on exposure, and the proportion of the population who stand to benefit; and (3) the magnitude of the relative risk of disease associated with the risk factor. This impact is quantified by the population impact fraction (PIF):[18]

126
$$PIF = \frac{\int p \, RR(x) \, dx - \int p'(x) \, RR(x) \, dx}{\int p(x) \, RR(x) \, dx}$$

where: x is the units of a risk factor (e.g. body mass index); p(x) is the prevalence of that risk factor; p'(x) is the prevalence of the risk factor after a scenario or intervention; and RR(x) is the relative risk

of disease associated with the risk factor. The PIF is age- and sex-dependent. Where there are background trends in the risk factor (e.g. obesity), the PIF is also time-dependent. Where diseases are influenced by multiple independent risk factors, PRIMEtime combines the PIFs multiplicatively:

132
$$PIF_{combined} = 1 - \prod_{i=1}^{n} (1 - PIF_i)$$

133 for $i = 1 \dots n$ diseases.

The relative risks of disease associated with each risk factor in PRIMEtime, have been drawn from 134 135 systematic reviews and meta-analyses. For modelling purposes, it is necessary to establish dose-136 response relationships across the entire distribution of risk factor exposure in the population of interest. Large, long-term randomised controlled trials are rare, and where they do exist, they provide 137 138 only limited variance between control and intervention arms in the risk factor of interest. Therefore, 139 establishing causality in the relationship between a risk factor and condition relies heavily on 140 prospective cohort studies, and evaluation of the entirety of evidence against criteria, such as those 141 of Bradford-Hill – strength and consistency of evidence, specificity, temporality, biological gradient, 142 plausibility, coherence, analogy and supporting experimental evidence.[19] In developing and 143 updating PRIMEtime we have preferentially drawn on systematic reviews and meta-analyses that take 144 these factors into account.

145 Disease models

Diet- and obesity-related diseases currently included in PRIMEtime include ischaemic heart disease, ischaemic stroke, intracerebral haemorrhage, hypertensive heart disease, diabetes mellitus type 2, colorectal cancer, breast cancer, uterine cancer, oesophageal cancer, kidney cancer, pancreatic cancer, liver cancer, multiple myeloma, asthma, low back pain, osteoarthritis of the hip and knee, depression, atrial fibrillation/flutter, and gallbladder/biliary diseases. 151 Cardiovascular diseases, diabetes and cancers are modelled in a three-state Markov model, in which 152 the population is either in a healthy state, a diseased state or dead (from the disease or from other un-related causes).[20] The initial distribution of the population between the healthy and diseased 153 154 states is determined by the prevalence of the disease in the baseline year. Further transition between 155 states over time is based on annual rates of incidence, remission and case fatality. However, for the 156 remaining PRIMEtime diseases that are chiefly characterised by morbidity rather than mortality (low back pain, osteoarthritis, depression, and gallbladder and biliary diseases) we do not model 157 158 progression to mortality.

PRIMEtime is designed to evaluate the effects of interventions, scenarios or system shocks in *preventing* disease and the consequent effects on population health and society. Therefore, we model the effects of a change in risk factor exposure, which is quantified by the PIF, as a change in disease incidence rate (*I*):

163
$$I'_{lag} = I \times (1 - PIF_{combined})$$

The calculation of I'_{lag} allows for a time lag in the reversal of disease risk. While there is an absence of direct evidence examining the time course for changes in disease rates following population changes in dietary intake or obesity, the World Health Organization has estimated it takes three to five years to achieve full reversal of stroke risk and around two-thirds of heart disease risk, from trials of blood pressure treatments.[21] Risk reversibility of cancers is likely to be longer, based on followup of patients around ten years after bariatric surgery or intentional weight loss.[22]

170 Population lifetable

171 In the population lifetable component of PRIMEtime, the population is divided into five-year age and 172 sex cohorts that are simulated through time. In a closed cohort simulation, the model is typically run 173 until everyone in the starting population is dead. In an open cohort simulation, which incorporates

future birth cohorts, the model can be run until the desired time horizon is reached or until there areno further birth cohorts entering the simulation.

Each population age- and sex- cohort is simulated in a proportional multi-state lifetable.[23] This consists of a standard lifetable model, which simulates the survival experience of a cohort based on age- and sex-specific mortality rates, connected with the series of disease-specific models described above. There are three key actions that occur in the proportional multi-state lifetable model.

First, when we simulate a change in prevalence of obesity, this influences incidence of obesity-related diseases, which, over time, lead to changes in disease-specific mortality rates. These changes in disease-specific mortality rates modify the total mortality rate in the main lifetable, while holding the proportion of mortality due to all other causes (i.e. causes not related to obesity) constant.

Second, everyone in the lifetable cohort who is alive has a utility weight, which reflects average (quality of life' at each age and sex. In the same way that total mortality in the lifetable is modified by changes in disease-specific mortality, the total utility in the lifetable is modified by changes in diseasespecific utility, which are derived in the disease-specific models from the change in incidence and/or prevalence of the disease and the disease-specific utility weight(s).

Third, everyone in the lifetable cohort who is alive has an average cost associated with their health care. This cost increases or decreases, based on changes in rates of obesity-related diseases, which are derived in the disease-specific models from the change in incidence and/or prevalence of the disease and the disease-specific health care cost.

Together, the lifetable, disease-specific and risk factor exposure models simulate each cohort ageing, over time, until everyone is dead, has reached 100 years of age, or the simulation has reached the end of its time horizon. From these simulations, PRIMEtime can determine the effect of a change in prevalence of a risk factor on: (a) population life expectancy; (b) gain or loss of quality-adjusted life years (QALYs); and (c) impact on costs to the health or social care system.

198 Country-specific input data

199 Population and mortality

200 PRIMEtime can be adapted for any country context with a number of country-specific inputs. 201 Population is entered by sex and 5-year age group, with the exception of the 0 to 4 year old group, 202 which is split into 0 year olds and 1 to 4 years olds to facilitate calculation of life expectancy at birth. 203 To run a closed cohort analysis, only the population in the baseline year of analysis is required. If 204 running an open cohort analysis, future cohorts of 0 to 4 years olds can be estimated from population 205 projections. The model currently has capacity to accept new entrants into the modelling until 2050. 206 PRIMEtime also requires mortality rates from all causes by sex and single year of age, from age 0 to 207 100+.

208 Both mortality rates and population numbers can be downloaded in the required format from the 209 Human Mortality Database[24] for 41 countries and, in some cases, also by population sub-groups, 210 e.g. by ethnicity. The Institute of Health Metrics Results Tool[25] also provides links to their collations 211 of population, mortality and life table data for Global Burden of Disease analyses, which is an 212 alternative source of data for countries not included in the Human Mortality Database or if within-213 country data collections are not accessible. These sources currently provide data up to 2019. Population estimates for later years (e.g. for open cohort analyses incorporating future birth cohorts) 214 215 are based on population projections. The United Nations provide a database of global population 216 projections if local estimates are not available.

217 Disease epidemiology

Population-specific disease rates can be derived from a variety of sources such as death and disease registries and disease-specific studies. Alternatively, PRIMEtime users can draw on Global Burden of Disease (GBD) syntheses of these sources. Cause-specific incidence, prevalence and mortality rates can be downloaded, by age and sex, using the GBD Results Tool.[25] These data can be used in

PRIMEtime for non-commercial purposes under the Creative Commons Attribution-Non Commercial4.0 International License.[26]

224 A key challenge in populating the PRIMEtime model is the requirement for cause-specific case fatality 225 rates. In the PRIMEtime model, the case fatality reflects the excess mortality of someone with the 226 disease compared with someone who does not have the disease. These rates are rarely reported, 227 however they can be derived from cause-specific incidence, prevalence and mortality rates, together 228 with population numbers and all-cause mortality rates, using the *disbayes* R package, which can be 229 found on the GitHub repository.[27] This package is recommended as, using a Bayesian approach, it 230 estimates case fatality using the same three-state model and assumptions that underpin disease 231 simulation in the PRIMEtime model, so consistency in approach is maintained.

Background trends in cause-specific incidence and case fatality rates can be estimated by fitting models to rates derived over multiple years. The GBD Results Tool[25] contains yearly estimates of rates from 1990.

235 Risk factor exposure

Prevalence of risk factors can be derived from population survey data. PRIMEtime is designed to take the mean and standard deviation of the distribution of risk in the population, by age and sex. This allows the population impact fraction to be calculated continuously (e.g. where the relative risk is defined per unit of BMI) or categorically (e.g. where relative risks are defined for overweight and obese categories of prevalence). There is also an option for taking background trends in risk factors into account.

Derivation of risk factor prevalence and trends depend on the availability of survey data, which is highly country-specific. Cobiac et al[8] provides an example of deriving trends in body mass index from health survey data in England. However, some global collations of data also exist, such as the World Health Organization Global Health Observatory[3] and the Global Dietary Database.[28]

246 Costs

267

247	There is currently no global database of age- and sex-specific costs of disease treatment in different
248	countries. For PRIMEtime analyses in the UK, the unit costs of treatment for the explicitly modelled
249	diseases and the average costs associated with health care for all other diseases, have been derived
250	from a range of administrative datasets. Briggs et al.[29] have published a detailed description of these
251	methods.
252	Model Implementation
253	Simulation options
254	PRIMEtime provides a number of options for evaluation. The user can:
255	 define discount rates for health and cost impacts;
256	 define time horizons for population simulation and for output of data;
257	 set time lags on the effects of a risk factor on diseases;
258	 include or exclude background trends in risk factors;
259	 include or exclude diseases; and
260	- select population cohorts for simulation (a closed cohort analysis only simulates outcomes for
261	the population alive in the baseline year of analysis, whereas an open cohort analysis also
262	simulates outcomes for those born in future years).
263	These choices depend on the purpose of the PRIMEtime simulation. For example, calculating cost-
264	effectiveness or return-on-investment of an intervention, will generally require discounting of cost
265	and health outcomes. Comparing cost-effectiveness of multiple preventive interventions can generally
266	be performed using a closed cohort simulation, since the relative performance of different

268 experience health benefits until well into the future. However, an open cohort simulation may be

interventions is unlikely to be greatly impacted by the addition of future birth cohorts who will not

preferred if PRIMEtime is being used to simulate impacts of a scenario on rates of obesity-related
diseases or costs of treating these diseases, over time into the future.

271 Scenario specification

PRIMEtime currently allows for simultaneous simulation of up to five scenarios or population subgroups. While the model can be run any number of times for different evaluations, simultaneous simulation facilitates analyses where uncertainty in the relative order of or difference between scenarios or sub-groups is important. For example, by simultaneously simulating outcome by quintile of Index of Multiple Deprivation, it is possible to estimate uncertainty in the slope index of inequality, a measure of health inequality.

278 Probabilistic Sensitivity Analysis

279 The PRIMEtime model is designed to be run iteratively. If only one iteration is performed, the model 280 will produce point-estimates of outputs based on the mean values of model input parameters. 281 However, when run many times, the model will randomly select from uncertain distributions around 282 input parameters to produce a range of outputs, from which mean or median values and 95% 283 uncertainty intervals can be determined. The degree of uncertainty in outputs depends on the number 284 of inputs that are uncertain, and the distribution of uncertainty around those inputs. As a rule-of-285 thumb, we recommend running as many iterations as are required to achieve stability in outputs to 286 the desired number of significant figures. Typically, this is between 2000 and 5000 iterations.

287 PRIMEtime evaluation of obesity interventions

288 Intervention specification

We demonstrate use of the PRIMEtime model in evaluating three interventions for addressing obesityin the UK population:

291 1. Implementing a Soft Drinks Industry Levy (SSB tax)

- Banning television advertising of foods and drinks high in fat, sugar, and salt (HFSS) between
 5:30 AM and 9:00 PM (TV ad bans).
- Offering total diet replacement to adults (18+ years) with a BMI greater than 30 kg/m² (Weight
 loss program).
- 296 Intervention effects were derived from previously published analyses as described in Table 1. For this
- study, we evaluated the interventions individually and additionally evaluated a combination of all
- three interventions, as if rolled out in the UK population from a baseline year of 2015.

299 UK data inputs

- 300 For the obesity intervention evaluation, we populated the PRIMEtime model with data for the UK.
- Table 2 described the data sources and assumptions made, and Text S1 provides the data as entered
- 302 into PRIMEtime.
- 303 Table 1 Intervention scenarios

Target group	Per person effect	Source
SSB tax		
Whole	-1.8 kcal (-3.1 to -0.50)*	Estimated from the results of interrupted time series
population		analyses of weekly household reductions in purchasing
		of sugar in drinks before and after the SDIL,[30]
		assuming an average of 2.4 people per household,[31]
		and a calorie content of 3.75 kcal per gram of
		sugar.[32]
TV ad bans		
Children aged 5	-9.1 kcal (-18 to -0.50)*	Estimated by Mytton et al,[14] assuming a complete
to 17 years		withdrawal of HFSS advertising between 5:30 AM and
		9:00 PM, a mean ad duration of 25.9 seconds (standard

> deviation 11.9 seconds) and an association between a child's daily energy intake and ad viewing for high fat, sugar and salt foods and drinks of 14.2 kcal per minute (0.7 to 27.7). We assumed that modelled changes in BMI at age 17 years would be sustained through adulthood.

Weight loss program

Adults aged ≥18	-7.2 kg (-9.4 to -4.9) at a	Estimated by Kent et al.[13] from the results of a
years with a	cost of 2017GDP796	randomised controlled trial of a total diet replacement
BMI>30 kg/m ²	per person	programme for weight management in primary care.
		We assumed a weight regain of 27.2 grams per month
		(18.4 to 35.9) based on the results of a systematic
		review and meta-analysis of trials reporting weight
		regain following weight loss intervention.[33]
		We assumed the intervention would be offered to all
		registered patients with a BMI>30kg/m ² . Rates of
		eligibility and willingness to participate, were based on
		the results of the randomised controlled trial.[34, 35]

Combination

As per individual	As per individual	The calorie effect of the SSB tax (via sugar reduction)
interventions	interventions	and the calorie effect of the TV ad bans are assumed to
		be additive in childhood. As with the individual analysis
		of the TV ad bans intervention, the difference in BMI
		due to the intervention at age 17, is assumed to be
		maintained into adulthood when the interventions are

combined. The combined analysis takes into account

the impact of the SSB tax and TV ad bans on the

proportion of adults who are obese and therefore

eligible for the weight loss program.

NB. Values are expressed as means and 95% confidence intervals, except where otherwise noted.

* Impact on body weight (kg) estimated using energy balance model predictions from Hall et al.[36,

37]

304

305 Table 2 PRIMEtime data inputs

PRIMEtime data input	Source
Population numbers	UK population numbers were determined by 5-year age group and sex
	from the Human Mortality Database.[24] Future cohorts of 0-4 year
	olds were derived by sex from the Office for National Statistics
	(principal projection).[38]
All-cause mortality rates	UK all-cause mortality rates were taken from the Human Mortality
	Database,[24] by single year of age and sex.
Background trends in	Predicted trends in overweight and obesity were taken from models
overweight and obesity	fitted to 27 years of Health Survey for England data, by Cobiac et al.[8]
	We assumed BMI trends in PRIMEtime would follow the non-linear
	model in base case analyses and the linear model in sensitivity
	analyses.
Disease rates – incidence,	Incidence and case fatality rates were derived from Global Burden of
case fatality and starting	Disease[39] estimates of incidence, prevalence and mortality, using
prevalence	disbayes.[27] Spline models were used to smooth data by age.

Background trends in	We approximated average annual trends in incidence and case fatality
disease incidence and case	rates, by sex and age group (0-34 years; 35-64 years; 65+ years), from
fatality	the difference in rates between 1995 and 2005 for model validation,
	and between 2005 and 2015 for intervention analyses.
Relative risks	We derived relative risks of obesity-related diseases from systematic
	reviews that had been published up to January 2021.
Utility weights	Parameters for estimating disease-specific and background utility
	weights were taken from a UK catalogue of EQ-5D scores.[40]
Disease costs	We estimated an average cost per prevalent case of each modelled
	disease, by determining: (a) the total costs of disease treatment from
	Department of Health and Social Care budget allocations to primary,
	hospital, community and specialised care services in England; then (b)
	dividing the total cost by the average number of prevalent cases.[25]
	We also estimated an overall average cost of health care from the
	total budget allocation for all diseases, divided by the number of
	people in the population.[24] Further details of these methods are
	provided in Text S2.
	The health care costs were estimated for the 2018-19 budget year and
	adjusted to the 2015 modelling baseline year using CPI adjustors.[41]

306

307 Model validation

To validate the epidemiological modelling, we additionally populated PRIMEtime with UK data for a baseline year of 2005, then ran the model forward in time to 2015 and compared simulated prevalence estimates for all cardio-metabolic diseases and cancers with other published data. For

311 comparison we used: (1) GBD estimates of prevalence in the year 2015;⁷ and (2) estimates of

prevalence for the period 2010-2015, from an analysis of linked clinical datasets by Kuan et al.[42]

313 Intervention evaluation

314 To simulate impact of the interventions on obesity prevalence, we ran an open cohort analysis from 2015 to 2050, adding new entrants to the population based on UK population projections. To simulate 315 316 overall impact on population health (QALYs) and health care costs, we ran a closed cohort analysis 317 over the lifetime of the population alive in 2015. QALYs and costs were discounted using HM Treasury 318 rates of 3.5% costs and 1.5% health (0 to 30 years), 3% costs and 1.29% health (31-75 years) and 2.5% 319 costs and 1.07% health (76-125 years).[43] We also calculated the net monetary benefit of each 320 intervention and the combination of interventions, which reflects the value of each option in 321 monetary terms, assuming a willingness-to-pay threshold for health.[44] For these calculations we 322 assumed a value of £60,000 per QALY, as recommended by HM Treasury.[45]

323 Results

324 Model validation

325 Figure 2 illustrates the results of the model validation runs, and full results can be found in Table S1 326 (PRIMEtime vs. GBD) and Table S2 (PRIMEtime vs. Kuan et al) in the supplementary appendix (Text 327 S3). Overall, estimates from PRIMEtime were slightly higher than estimates from GBD for 13 out of 14 328 diseases, and slightly lower than estimates from Kuan et al for 12 out of 13 diseases (Kuan et al did 329 not have a comparable disease category for hypertensive heart disease). The absolute difference in 330 the prevalent proportion of the population with disease was less than 1 percentage point for 12 out 331 of 14 diseases in comparison with the GBD estimates, and for 11 out of the 13 diseases in the 332 comparison with the Kuan et al estimates. We found the largest percentage differences for diabetes 333 (Kuan et al 2.7 percentage points lower; GBD 2.5 percentage points higher) and atrial fibrillation and

flutter (Kuan et al 2.5 percentage points higher). The mean absolute percentage error across all
outcomes was 0.12 percentage points.

336 Prevalence of overweight and obesity

337 The modelling shows that all of the interventions are likely to reduce population prevalence of 338 overweight and obesity over time, but the pattern of impact varies between interventions (Figure 3). 339 Restricting television advertising of unhealthy foods has the largest impact in reducing overweight and 340 obesity overall, with effects concentrated during childhood. The reduction in prevalence starts at 341 around 0.31 percentage points (95% uncertainty interval: 0.021 to 0.58) for males and 0.34 percentage 342 points (0.023 to 0.65) for females, then increases over time as more children are born and exposed to 343 the intervention. The sugar-sweetened beverage tax also has a slightly smaller impact; benefiting both 344 children and adults, it achieves a reduction in prevalence of overweight and obesity of around 0.19 345 percentage points (0.058 to 0.31) for males and 0.20 percentage points (0.063 to 0.34) for females 346 initially, and remains relatively stable through time (Text S3 – Table S3). The weight loss program, while very effective for the obese adult population who participate in the program, has the smallest 347 348 overall effect on population prevalence of overweight and obesity, initially reducing prevalence by just 349 0.022 percentage points (0.015 to 0.030) for males and 0.027 percentage points (0.018 to 0.037) for 350 females, with lessening benefit over time due to weight regain among participants. The best outcomes 351 are achieved by combining the interventions, which leads to an initial reduction in population 352 prevalence of overweight and obesity of 0.51 percentage point (0.20 to 0.82) for males and 0.57 353 percentage points (0.22 to 0.90) for females. This reduction increases over time, to around 0.81 percentage points (0.21 to 1.4) for males and 0.95 percentage points (0.24 to 1.7) for females by the 354 355 end of the simulation in 2050.

356 Cases of disease

357 Due to the modelled improvements in overweight and obesity prevalence, all of the modelled 358 interventions lead to a reduction in incidence of disease (Table 3). The size of the impact of each

359 intervention, in the first ten years of implementation is strongly influenced by the nature of the target 360 population. The sugar-sweetened beverage tax, which is designed to have an effect across all groups 361 in the population, has the largest benefits in reducing disease in the first ten years. The biggest impact 362 is on cases of type 2 diabetes, followed by cardiovascular diseases and cancers. While restricting 363 television advertising of unhealthy foods to children has larger impacts on overweight and obesity 364 than the SSB tax, it has relatively little effect on cases of disease in the first ten years, since it is 365 targeting children, who will not experience the benefits of disease prevention until some years into 366 the future. The weight loss program, on the other hand, has immediate benefits in reducing cases of 367 type 2 diabetes, cardiovascular diseases and cancers, since it is targeting obese adults, who are at 368 highest risk of developing obesity-related diseases. When combined, the interventions are predicted 369 to prevent 15,000 (95% uncertainty interval: 6,600 to 24,000) cases of type 2 diabetes, 4,900 (2,200 370 to 7,700) cases of cardiovascular diseases and 460 (220 to 720) cases of cancer in the first ten years of 371 implementation.

Table 3 Impact of the intervention scenarios on incident cases of disease in the first ten years (rounded to two significant figures).

Disease group*	Female	Male	Total
SSB tax			
Type 2 diabetes	-5,300 (-9,200 to -	-6,400 (-11,000 to -	-12,000 (-20,000 to -
	1,600)	1,900)	3,500)
Cardiovascular diseases	-1,500 (-2,600 to -	-2,300 (-4,000 to -	-3,900 (-6,600 to -
	480)	730)	1,200)
Cancers	-240 (-410 to -75)	-110 (-190 to -33)	-350 (-600 to -110)
TV ad bans			
Type 2 diabetes	0.0039 (0.0003 to	0.0047 (0.0003 to	0.0086 (0.0005 to
	0.0078)	0.0094)	0.017)
Cardiovascular diseases	-0.16 (-0.32 to -0.011)	-0.23 (-0.46 to -0.015)	-0.38 (-0.79 to -0.026)

Cancers	-6.9 (-14 to -0.48)	-1.3 (-2.6 to -0.08)	-8.2 (-16 to -0.56)
Weight loss program			
Type 2 diabetes	-1,500 (-2,200 to -	-1,700 (-2,400 to -	-3,200 (-4,600 to -
	920)	1,000)	1,900)
Cardiovascular diseases	-440 (-640 to -270)	-650 (-930 to -400)	-1,100 (-1,600 to -
			670)
Cancers	-73 (-100 to -46)	-32 (-46 to -20)	-110 (-150 to -66)
Combination			
Type 2 diabetes	-6,800 (-11,000 to -	-8,100 (-13,000 to -	-15,000 (-24,000 to -
	3,100)	3,500)	6,600)
Cardiovascular diseases	-2,000 (-3,100 to -	-3,000 (-4,700 to -	-4,900 (-7,700 to -
	890)	1,300)	2,200)
Cancers	-320 (-500 to -150)	-140 (-230 to -67)	-460 (-720 to -220)

* Table S4 in the supplementary appendix (Text S3) shows modelled impact on individual diseases within each group.

374

Population health and health care costs 375

When modelled over the lifetime of the UK population, all of the interventions lead to a health gain 376 377 for the population and a reduction in health care spending, and all interventions have a positive net 378 monetary benefit from a health sector perspective (Table 4). The combination of interventions is 379 estimated to produce a population health gain of 519,000 (201,000 to 837,000) QALYs and offset £299 380 (£121 to £515) million in health sector spending, achieving a net monetary benefit of £31,400 (12,200 to 50,700) million. 381

382 Table 4 Lifetime impact of the intervention scenarios on population health and health care costs, and the net monetary benefit 383 of the scenarios

Scenario	Health impact (QALYs)	Cost offsets (£million)	Net monetary benefit
			(£million)
SSB tax	200,000 (61,200 to	-128 (-237 to -37.5)	12,100 (3,710 to
	345,000)		20,900)
TV ad bans	302,000 (19,900 to	-159 (-331 to -11.2)	18,300 (1,200 to
	588,000)		35,600)
Weight loss program	18,600 (8,580 to	-12.2 (-26.2 to -2.82)	1,130 (519 to 2,020)
	33,300)		
Combination	519,000 (201,000 to	-299 (-515 to -121)	31,400 (12,200 to
	837,000)		50,700)

384

Uncertainty 385

386 Uncertainty around intervention effects on sugar intake (SSB tax), calorie intake (TV ad bans) or weight 387 change (Weight loss program) have the biggest influence on uncertainty in the model predictions of health gain, health sector cost offsets and net monetary benefit (Figure 4). The uncertainty in relative 388 389 risks of obesity-related diseases, utility values quantifying quality of life, and disease unit costs are less 390 influential. Results are similar when the interventions are evaluated individually (Text S3 – Figure S1).

Sensitivity 391

392 The modelled net monetary benefit remained positive in all sensitivity scenarios we evaluated (Text 393 S3 – Figure S2). The magnitude of net monetary benefit is most strongly influenced by the preferred 394 discount rates. The outcome is more favourable with lower or no discounting, since this effectively 395 gives more weight to future health gains and averted health care costs. Whereas the net monetary benefit is less favourable (although still positive) with a higher discount rate overall, or when the rate 396 397 of discounting of health gains is increased more than costs, (e.g. when changing to NICE rates). Net 398 monetary benefit does not vary substantially with variations in the modelled background trends in 399 BMI distribution, background trends in disease incidence and case fatality rates, and assumed lags in 400 effect of BMI changes on disease incidence. Increasing the number of modelled obesity-related 401 diseases included in the simulation does influence the magnitude of impact on health and health care 402 costs, but the overall impact on net monetary benefit is small.

403 Discussion

404 Main findings and interpretation

In this paper we have described the PRIMEtime model, a tool for evaluating health and economic impacts of diet and obesity policies. The model uses routinely available epidemiological data to simulate the effects of changes in diet and obesity on 19 non-communicable diseases, over the lifetime of the population, or out to the year 2050 if including future birth cohorts. From these simulations, the model can estimate impact of a policy on population health (overweight and obesity prevalence, cases of disease averted, quality-adjusted life years gained), health and social care costs, and economic measures (net monetary benefit, cost-effectiveness ratios).

The PRIMEtime modelling of a SSB tax, a ban on television advertising of unhealthy foods, and a weight loss program illustrates the potentially wide variation in impact of interventions on prevalence of overweight and obesity, and subsequent changes in health and the need for health care. This variation is due to both the characteristics of the intervention and population that is targeted.

While reductions in TV advertising of unhealthy foods to children has the largest impact in reducing prevalence of overweight and obesity, the SSB tax has much larger and more immediate benefits in reducing disease. The weight loss program also has immediate benefits in improving health despite relatively small benefits in reducing overweight and obesity on a population-scale. The variability in impact, both by age and over time, demonstrates the importance of using models to determine how best to combine intervention strategies to achieve maximum population benefit.

From a health sector perspective, the modelling shows that all three policies will likely have a positive net monetary benefit. This would suggest that all three of the obesity interventions are a good investment for HM Treasury. However, even when combined these three interventions are predicted to reduce prevalence of overweight and obesity by less than 1 percentage point by 2050. With almost a third of children and two-thirds of adults currently overweight or obese,[5] much more will be needed to address the problem.

428 Study strengths and limitations

429 While PRIMEtime is not primarily designed for forecasting disease rates, the accuracy of the 430 underlying epidemiological model will nevertheless impact on the absolute magnitude of its outputs, 431 such as QALYs and health care costs. Therefore it is reassuring that in validation PRIMEtime simulated 432 future prevalence of diseases close to estimates from GBD and Kuan et al.[42] (<1 percentage point 433 difference for 85% of estimates). For the majority of diseases, prevalence estimates from PRIMEtime were slightly higher than those from GBD and slightly lower than those from Kuan et al. This may partly 434 435 relate to differences in the way that the two comparison studies have arrived at their estimates. The 436 GBD collates data from a variety of sources, such as surveys, registries and published studies, and uses 437 statistical models to estimate country-specific disease rates that are regionally and globally consistent. 438 Whereas, Kuan et al have derived prevalence by analysing electronic health records from the primary 439 care Clinical Practice Research Datalink linked with hospital admissions records from Hospital Episode 440 Statistics, using a newly developed system of algorithmic phenotyping to identify cases of disease. [46] 441 The linked databases are considered representative of the English population, [47] which constitutes 442 around 85% of the UK population that we simulated in PRIMEtime.

Other reasons for differences between PRIMEtime predictions and later estimates may include changes in incidence or case fatality rates that were not captured by trend estimates (e.g. due to increased or decreased funding of prevention or treatment practices) and assumptions embedded in the epidemiological modelling. PRIMEtime simulates the epidemiology using a *proportional* multi-

447 state lifetable design.[23] In a standard multi-state lifetable model, an individual or population cohort 448 transition from one state to another (e.g. from healthy, to having disease X, to dying from disease X or other causes). But as additional diseases are added to the simulation, the model quickly becomes 449 450 intractable due the need for additional disease states (e.g. having disease X only, having disease Y only 451 and having diseases X and Y) and data required to quantify rates of transition between these many 452 states. A proportional multi-state lifetable model overcomes this problem by allowing the individual 453 or population cohort to proportionally exist in multiple disease states. This approach potentially has 454 an advantage in modelling health impacts of *preventive* interventions, where a change in population 455 exposure to a risk factor, can influence many diseases. However, implicit in allowing a population 456 cohort to proportionally exist across multiple disease states is the assumption that the diseases are 457 independent. In some cases, this assumption is clearly violated. For example, prevalence of diabetes 458 increases risk of both heart disease[48] and stroke,[49] even when adjusted for baseline 459 cardiovascular risks such as obesity. In PRIMEtime, we adjust for the dependence between diabetes 460 and cardiovascular disease outcomes, by treating diabetes as both a risk factor and a disease in the 461 model structure. But data to explicitly incorporate other possible relationships, such as between 462 cancer prevalence and cardiovascular outcomes, are limited.

While the proportional multi-state lifetable approach does involve some trade-offs, the methods are widely used in modelling tools designed to evaluate health and economic impacts of diet and obesity interventions (e.g.[50-55]). Models that do not take this approach, typically only simulate one disease (e.g. the Coronary heart disease (CHD) policy model[56, 57]) or estimate changes in incidence and/or mortality of diseases without addressing co-morbidity (e.g. the Foresight model,[58]) thus sacrificing capacity to simulate changing effects on quality of life and health care costs through time.

PRIMEtime is primarily designed for scenario evaluation. It is a tool that can be used to compare future
impacts of policies, under a common set of assumptions about future unknowns, and to explore
uncertainties in potential outcomes, in order to help set priorities for action and better understand

472 risks associated with decisions. Uncertainty bounds reflect best estimates of the likely range of 473 outcomes, but will never capture impacts of future unpredictable events, such as the emergence of 474 new pandemic diseases. Thus, the true strength of simulation is in comparison of alternative policy 475 options under the same set of assumptions. And these assumptions must be updated as knowledge 476 develops. For example, the selection of diet- and obesity-related diseases in PRIMEtime, and 477 quantification of the dose-response relationships, as captured in Table S4 and Table S5 478 (supplementary appendix Text S1) should be regularly revisited and updated as new systematic 479 reviews and meta-analyses are published.

480 Potential policy and research implications

481 The three interventions we have evaluated in PRIMEtime are all components of the UK government's 482 latest obesity strategy.[17] The SSB tax was implemented as a Soft Drinks Industry Levy in 2018;[59] 483 and a 9pm watershed on advertising of high fat, salt and sugar foods, is scheduled to come into effect 484 at the end of 2022.[60] While weight loss programs for those who are already obese are recommended, as of mid-2021, there do not appear to be specific plans for added funding. While the 485 486 modelling indicates that all three are a good investment, the relatively small overall impact on the 487 high prevalence of overweight and obesity in the UK suggests that much more will be required to 488 improve health and reduce the associated costs of care.

489 A broader range of interventions targeting dietary intake and obesity may be beneficial for health in 490 the UK, but it is likely that we also need to give greater consideration to the structural and systemic 491 changes that are needed in our society to address the underlying drivers of the obesity epidemic. With 492 globalisation has come enormous shifts in the way that we work, travel, produce and distribute food, 493 which have impacted on both our dietary intake and energy expenditure.[61] While the underlying drivers and feedback mechanisms are sometime complex, [62] the last decade has seen big advances 494 in the way that we can collect and make use of data to better understand these forces, as well as big 495 496 advances in the tools available to build and run models. Since the early 2000s there has been rapid

497 growth in the development and use of models to find cost-effective interventions that directly target 498 physical activity, dietary intake and obesity.[63, 64] But models can potentially now play a much 499 broader role in simulating impacts of policies or trends that impact on the food system or active 500 environment, either directly or indirectly. In the future, integration of health models, such as 501 PRIMEtime, with models the simulate the complexities of our economies and changing climate, may 502 help us better understand and address the underlying drivers of the obesity epidemic.

503 References

- 1. Williams G, Fruhbeck G. Obesity: science to practice: John Wiley & Sons; 2009.
- 505 2. Caballero B. The global epidemic of obesity: an overview. Epidemiol Rev. 2007;29(1):1-5.
- 506 3. The Global Health Observatory: Indicators: World Health Organization; [13 May 2021]. Available
 507 from: https://www.who.int/data/gho/data/indicators.
- 508 4. Dai H, Alsalhe TA, Chalghaf N, Riccò M, Bragazzi NL, Wu J. The global burden of disease
- 509 attributable to high body mass index in 195 countries and territories, 1990–2017: An analysis of the
- 510 Global Burden of Disease Study. PLoS Med. 2020;17(7):e1003198.
- 5. Health Survey for England. UK: NHS Digital.
- 512 6. Theis DR, White M. Is obesity policy in England fit for purpose? Analysis of government strategies
- 513 and policies, 1992–2020. The Milbank Quarterly. 2021;99(1):126-70.
- 514 7. Jebb S, Aveyard P, Hawkes C. The evolution of policy and actions to tackle obesity in E ngland.
- 515 Obes Rev. 2013;14:42-59.
- 516 8. Cobiac LJ, Scarborough P. Modelling future trajectories of obesity and body mass index in
- 517 England. PLoS ONE. 2021;16(6):e0252072. doi: 10.1371/journal.pone.0252072.

518 9. Metcalf CJE, Edmunds W, Lessler J. Six challenges in modelling for public health policy. Epidemics.

519 2015;10:93-6.

- 520 10.Webber L, Mytton OT, Briggs ADM, Woodcock J, Scarborough P, McPherson K, et al. The Brighton
- 521 declaration: the value of non-communicable disease modelling in population health sciences. Eur J
- 522 Epidemiol. 2014;29(12):867-70. doi: 10.1007/s10654-014-9978-0.
- 523 11.Cobiac LJ, Scarborough P, Kaur A, Rayner M. The Eatwell guide: Modelling the health implications
- of incorporating new sugar and fibre guidelines. PLoS ONE. 2016;11(12):e0167859.
- 525 12.Briggs AD, Cobiac LJ, Wolstenholme J, Scarborough P. PRIMEtime CE: a multistate life table model
- 526 for estimating the cost-effectiveness of interventions affecting diet and physical activity. BMC Health
- 527 Serv Res. 2019;19(1):485.
- 528 13.Kent S, Aveyard P, Astbury N, Mihaylova B, Jebb SA. Is Doctor Referral to a Low-Energy Total Diet
- 529 Replacement Program Cost-Effective for the Routine Treatment of Obesity? Obesity. 2019;27(3):391-

530 8.

- 531 14.Mytton OT, Boyland E, Adams J, Collins B, O'Connell M, Russell SJ, et al. The potential health
- 532 impact of restricting less-healthy food and beverage advertising on UK television between 05.30 and
- 533 21.00 hours: A modelling study. PLoS Med. 2020;17(10):e1003212.
- 534 15. Alonso S, Tan M, Wang C, Kent S, Cobiac L, MacGregor GA, et al. Impact of the 2003 to 2018
- 535 Population Salt Intake Reduction Program in England: A Modeling Study. Hypertension.
- 536 2021;77(4):1086-94.
- 537 16.Cobiac LJ, Scarborough P. Modelling the health co-benefits of sustainable diets in the UK, France,
- 538 Finland, Italy and Sweden. Eur J Clin Nutr. 2019;73(4):624-33.

539 17.Department of Health and Social Care. Tackling obesity: empowering adults and children to live

- 540 healthier lives. UK: Department of Health and Social Care, 2020.
- 541 18.Morgenstern H, Bursic ES. A method for using epidemiologic data to estimate the potential
- 542 impact of an intervention on the health status of a target population. J Community Health.

543 1982;7(4):292-309.

544 19.Hill AB. The environment and disease: association or causation? : Sage Publications; 1965.

545 20.Barendregt J, Oortmarssen GJ, Vos T, Murray CJL. A generic model for the assessment of disease

epidemiology: the computational basis of DisMod II. Popul Health Metr. 2003;1. doi: 10.1186/1478-

547 7954-1-4.

548 21.Lawes C, Vander Hoorn S, Law M, Elliott P. High blood pressure. In: Ezzati M, Lopez A, Rodgers A,

549 Murray C, editors. Comparative Quantification of Health Risks: Global and Regional Burden of

- 550 Disease Attributable to Selected Major Risk Factors. Geneva: World Health Organisation; 2004.
- 551 22.Renehan AG, Soerjomataram I, Tyson M, Egger M, Zwahlen M, Coebergh JW, et al. Incident

552 cancer burden attributable to excess body mass index in 30 European countries. Int J Cancer.

553 2010;126(3):692-702.

23.Barendregt JJ, Van Oortmarssen GJ, Van Hout BA, Van Den Bosch JM, Bonneux L. Coping with
multiple morbidity in a life table. Math Popul Stud. 1998;7(1):29-49.

- 556 24. University of California Berkeley (USA), Max Planck Institute for Demographic Research
- 557 (Germany). Human Mortality Database [5 May 2021]. Available from: <u>www.mortality.org</u>.

25.Institute for Health Metrics and Evaluation. Global Health Data Exchange: GBD Results Tool [5
May 2021]. Available from: http://ghdx.healthdata.org/gbd-results-tool.

- 560 26.Institute for Health Metrics and Evaluation. Terms and Conditions [5 May 2021]. Available from:
- 561 <u>http://www.healthdata.org/about/terms-and-conditions.</u>
- 562 27.Jackson C. disbayes [5 May 2021]. Available from: <u>https://github.com/chjackson/disbayes</u>.
- 563 28.Global Dietary Database: Tufts University; [13 May 2021]. Available from:
- 564 <u>https://www.globaldietarydatabase.org/</u>.
- 565 29.Briggs AD, Scarborough P, Wolstenholme J. Estimating comparable English healthcare costs for
- 566 multiple diseases and unrelated future costs for use in health and public health economic modelling.
- 567 PLoS ONE. 2018;13(5):e0197257.
- 568 30.Rogers N, Pell D, Mytton O, Penney T, Briggs A, Cummins S, et al. Changes in soft drinks
- 569 purchased by British households associated with the UK soft drinks industry levy: a controlled
- 570 interrupted time series analysis. BMJ Open (Under review).
- 571 31.Number of households by household size and age of household reference person (HRP), English
- regions and UK constituent countries, 2019 UK: Office for National Statistics; 2019 [22 June 2019].
- 573 Available from:
- 574 https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/families/adho
- 575 cs/11520numberofhouseholdsbyhouseholdsizeandageofhouseholdreferencepersonhrpenglishregion
- 576 <u>sandukconstituentcountries2019</u>.
- 577 32.FAO. Food energy methods of analysis and conversion factors. Rome: Food and Agriculture
- 578 Organization of the United Nations, 2003.
- 579 33.Hartmann-Boyce J, Theodoulou A, Oke JL, Butler AR, Scarborough P, Bastounis A, et al.
- 580 Association between characteristics of behavioural weight loss programmes and weight change after
- 581 programme end: systematic review and meta-analysis. bmj. 2021;374.

- 582 34.Jebb SA, Astbury NM, Tearne S, Nickless A, Aveyard P. Doctor Referral of Overweight People to a
- 583 Low-Energy Treatment (DROPLET) in primary care using total diet replacement products: a protocol
- for a randomised controlled trial. BMJ open. 2017;7(8).
- 585 35.Astbury NM, Aveyard P, Nickless A, Hood K, Corfield K, Lowe R, et al. Doctor Referral of
- 586 Overweight People to Low Energy total diet replacement Treatment (DROPLET): pragmatic
- 587 randomised controlled trial. bmj. 2018;362.
- 588 36.Hall KD, Butte NF, Swinburn BA, Chow CC. Dynamics of childhood growth and obesity:
- 589 development and validation of a quantitative mathematical model. The lancet Diabetes &
- 590 endocrinology. 2013;1(2):97-105.
- 591 37. Hall KD, Sacks G, Chandramohan D, Chow CC, Wang YC, Gortmaker SL, et al. Quantification of the
- effect of energy imbalance on bodyweight. Lancet. 2011;378(9793):826-37. PubMed PMID: S0140-
- 593 6736(11)60812-X.
- 594 38.Office for National Statistics. 2016-based National Population Projections 2017 [1 September
- 595 2020]. Available from:
- 596 https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationproje
- 597 ctions/datasets/z3zippedpopulationprojectionsdatafilesengland.
- 598 39.Global Burden of Disease Study 2015 (GBD 2015) Data Resources: Institute for Health Metrics and
- 599 Evalaution, University of Washington; 2016 [cited 2016 12 December 2016]. Available from:
- 600 <u>http://ghdx.healthdata.org/gbd-2015</u>.
- 40.Sullivan PW, Slejko JF, Sculpher MJ, Ghushchyan V. Catalogue of EQ-5D scores for the United
- 602 Kingdom. Med Decis Making. 2011;31(6):800-4.
- 41.CPI INDEX 06 : HEALTH 2015=100 United Kingdom: Office for National Statistics; [14 May 2021].
- 604 Available from: <u>https://www.ons.gov.uk/economy/inflationandpriceindices/timeseries/d7bz/mm23</u>.

- 42.Kuan V, Denaxas S, Gonzalez-Izquierdo A, Direk K, Bhatti O, Husain S, et al. A chronological map of
- 606 308 physical and mental health conditions from 4 million individuals in the English National Health
- 607 Service. The Lancet Digital Health. 2019;1(2):e63-e77.
- 43.HM Treasury. The Green Book: Central Government Guidance on Appraisaland Evaluation. UK:
- 609 HM Treasury, 2018.
- 610 44.Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. New York:
- 611 Oxford University Press; 2006.
- 45. Glover D, Henderson J. Quantifying health impacts of government policies 2010 21 October 2021.
- 613 Available from:
- 614 <u>https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file</u>
- 615 /216003/dh_120108.pdf.
- 616 46.Denaxas S, Gonzalez-Izquierdo A, Direk K, Fitzpatrick NK, Fatemifar G, Banerjee A, et al. UK
- 617 phenomics platform for developing and validating electronic health record phenotypes: CALIBER. J
- 618 Am Med Inform Assoc. 2019;26(12):1545-59.
- 47.Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, Van Staa T, et al. Data resource
- 620 profile: clinical practice research datalink (CPRD). Int J Epidemiol. 2015;44(3):827-36.
- 48.Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in
- women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507
- 623 individuals and 28,203 coronary events. Diabetologia. 2014;57(8):1542-51.
- 49.Peters SA, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with
- 625 men: a systematic review and meta-analysis of 64 cohorts, including 775 385 individuals and 12 539
- 626 strokes. Lancet. 2014;383(9933):1973-80.

- 50. Brown V, Ananthapavan J, Veerman L, Sacks G, Lal A, Peeters A, et al. The potential cost-
- 628 effectiveness and equity impacts of restricting television advertising of unhealthy food and
- 629 beverages to Australian children. Nutrients. 2018;10(5):622.
- 630 51.Cleghorn C, Jones A, Freeman L, Wilson N. Updated Cost-effectiveness Modelling of a Behavioural
- 631 Weight Loss Intervention Involving a Primary Care Provider. New Zealand: University of Otago, 2020.
- 632 52.Cobiac LJ, Vos T, Veerman JL. Cost-effectiveness of Lighten Up to a Healthy Lifestyle and Weight
- 633 Watchers. Report for Queensland Health. Centre for Burden of Disease and Cost-Effectiveness, The
- 634 University of Queensland, 2008.
- 635 53. Forster M, Veerman JL, Barendregt JJ, Vos T. Cost-effectiveness of diet and exercise interventions
- to reduce overweight and obesity. Int J Obes. 2011.
- 54. Jones AC, Veerman JL, Hammond D. The health and economic impact of a tax on sugary drinks in
 Canada. Waterloo (ON): University of Waterloo, 2017.
- 639 55.Bourke EJ, Veerman JL. The potential impact of taxing sugar drinks on health inequality in
- 640 Indonesia. BMJ global health. 2018;3(6):e000923.
- 56.Moran A, Zhao D, Gu D, Coxson P, Chen C-S, Cheng J, et al. The future impact of population
- 642 growth and aging on coronary heart disease in China: projections from the Coronary Heart Disease
- 643 Policy Model-China. BMC Public Health. 2008;8(1):1-14.
- 57. Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. Forecasting coronary
- heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. Am J Public
 Health. 1987;77(11):1417-26.
- 647 58.McPherson K, Marsh T, Brown M. Foresight. Tackling obesities modelling future trends in
- obesity and the impact on health. London: Government Office for Science, 2007.

- 59.HM Revenue & Customs. Soft Drinks Industry Levy: UK Government; 2016 [cited 2021 7 April
- 650 2021]. Available from: https://www.gov.uk/government/publications/soft-drinks-industry-levy/soft-
- 651 <u>drinks-industry-levy</u>.
- 652 60. Introducing further advertising restrictions on TV and online for products high in fat, salt and
- 653 sugar: government response: UK Government; 24 June 2021 [30 August 2021]. Available from:
- 654 <u>https://www.gov.uk/government/consultations/further-advertising-restrictions-for-products-high-</u>
- 655 in-fat-salt-and-sugar/outcome/introducing-further-advertising-restrictions-on-tv-and-online-for-
- 656 products-high-in-fat-salt-and-sugar-government-response.
- 657 61.Kawachi I, Wamala SP, ProQuest E, Oxford University P. Globalization and health. Wamala S,
- 658 Kawachi I, Kawachi I, Wamala S, editors. New York;Oxford;: Oxford University Press; 2007.
- 659 62. Tackling Obesities: Future Choices Project report. UK: Government Office for Science, 2007.
- 660 63.Cobiac LJ, Veerman L, Vos T. The role of cost-effectiveness analysis in developing nutrition policy.
- 661 Annu Rev Nutr. 2013;33:373-93.
- 662 64.Schwander B, Hiligsmann M, Nuijten M, Evers S. Systematic review and overview of health
- 663 economic evaluation models in obesity prevention and therapy. Expert review of
- 664 pharmacoeconomics & outcomes research. 2016;16(5):561-70.
- 665









SSB tax

TV ad bans

Weight loss program

Combination







